david siegel, md, explains the results of mm014 study presented at ash
Published 5 years ago • 59 plays • Length 2:58
Download video MP4
Download video MP3
Similar videos
-
2:15
david siegel, md, shares his thoughts on the daratumamab studies presented at ash 2018
-
1:31
david s. siegel, md, shares his thoughts on the most exciting clinical trial presented at ash 2017
-
1:49
david siegel, md, phd, regarding the early test results of cc-220 presented at ash 2020
-
4:35
david siegel, md, phd, summarizes outcomes from the phase i crb-402 study presented at ash 2020
-
2:28
david siegel, md, phd, shares details from the apollo & candor trial updates presented at ash '20
-
2:06
david siegel, m.d., phd, conducts critical research to develop new treatments for multiple myeloma
-
1:23
david siegel, md, phd, elaborates on outcomes from the karmma trial
-
0:55
david siegel, md, talks about the tourmaline-mm3 study and the treatment of multiple myeloma
-
2:21
mezigdomide: a novel celmod showing promise in the treatment of r/r myeloma
-
35:07
onclive news network on location: ash 2019 day 1
-
5:19
a 17-year fight against multiple myeloma
-
1:30
david s. siegel, md, on how molecular profiling is helping drive treatment strategies
-
1:21
david s. siegel, md, discusses proteasome inhibitors and multiple myeloma
-
1:01
david siegel, md, phd, on pomalidomide as an effective salvage therapy for mm patients
-
1:54
david siegel, md, phd, on pembrolizumab and lenalidomide in multiple myeloma treatment
-
1:29
david siegel, md, phd, regarding bispecific antibodies in the management of relapsed/refractory mm
-
1:26
david siegel, md, phd, on the potential of ft538, an engineered, off-the-shelf nk therapy
-
2:05
dr. siegel on the cost of cancer care
-
1:27
dr. siegel on the importance of bisphosphonates
-
1:41
dr. siegel discusses ongoing myeloma clinical trials
-
1:36
dr. siegel on distinguishing between classes of drugs in myeloma
-
2:07
dr. siegel on pomalidomide in lenalidomide-refractory patients with myeloma
Clip.africa.com - Privacy-policy